Induction Therapy Strategies for Treatment-Related AML
January 29, 2026 • AML Clinical Content Hub
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness for intensive therapy guides her decision. She notes that when patients are fit for intensive induction, she prefers using CPX-351 over the traditional 7+3 regimen based on data showing improved overall survival, and for patients unfit for intensive induction, she considers hypomethylating agents plus venetoclax as an alternative.
